Venlafaxine Hydrochloride
Product Images NDC 68071-2703

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68071-2703). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2703 3)

This is a medication warning label for Venlafaxine Hydrochloride 75mg capsules. The medication is available as a prescription and should be kept out of reach of children. The label lists the medication's lot number and expiration date, as well as its manufacturer and ingredients. Users are advised to contact their doctor for medical advice on possible side effects and to report any side effects to the FDA. The medication should be stored at controlled temperatures between 68-77°F.*

FDA Label Image

Figr1 (Figr1)

This text appears to be a list of drugs and their potential interactions with other drugs, as well as information on how those interactions may affect the PK Fold Change and 90% CI Recommendation (pharmacokinetics) of the drugs. The list includes drugs such as Ethanol, Diazepam, Cimetidine, Ketoconazole, Indinavir, Metoprolol, Imipramine, and Lithium, and their interactions with the drug Venlafaxine. The text also includes recommendations for dosing and cautionary use with certain patient populations for some of the drugs listed.*

FDA Label Image

Figr2 (Figr2)

This is a list of drugs with potential interactions and corresponding recommendations based on the change in pharmacokinetic parameters (Cmax and AUC) and the 90% Confidence Interval (CI). The drugs include ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium. The recommendations range from "avoid concomitant use" to "no dose adjustment" but there were some cases where the clinical significance of the interaction was unknown. The list also provides the fold change relative to the reference value for each drug.*

FDA Label Image

Figr3 (Figr3)

This appears to be a table or chart with information regarding the effects of various conditions on the dosage recommendations for the drug venlafaxine for different patient populations. The conditions listed include hepatic impairment (cirrhosis, mild impairment, moderate impairment), renal impairment (hemodialysis), CYP2D6 polymorphism, age (>60 years), and gender (females/males). The parameters considered for dosage adjustment include Cmax and AUC, and individualization of dosing may be necessary for certain population groups. The chart also includes fold change and 90% confidence intervals for each population group.*

FDA Label Image

Logo1 (Logo1)

FDA Label Image

Logo2 (Logo2)

FDA Label Image

Venlafaxinestructure (Venlafaxinestructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.